| Issue | Title | |
| Vol 2003, No 35 (2003) | Hormos Medical Corp. | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 5 (2010) | Hospira and Javelin Pharmaceuticals Enter Into Definitive Merger Agreement | Abstract |
| Debbie Tranter | ||
| Vol 2012, No 9 (2012) | Hospira Boosts Antibiotic Business with Acquisition of Orchid’s API Facilities | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 12 (2009) | Hospira in Leukaemia Deal and Buys Indian Injectables Business | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 76 (2006) | Hospira to Acquire Mayne Pharma | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | How 'Good' is Your Deal Sheet? | Abstract html |
| Fintan Walton | ||
| Vol 2007, No 84 (2007) | How Companies Source their Licensing Opportunities, Part I: The Need to Partner Continues to Grow | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | How Companies Source Their Licensing Opportunities, Part II: The Importance of Personal Networks | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 86 (2007) | How Companies Source their Licensing Opportunities, Part III: PharmaVentures's Approach to Increasing the Quality of the Target Candidate List and the Speed of the Licensing Process | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 1 (2009) | How to Survive in Tough Economic Times | Abstract html |
| Fintan Walton | ||
| Vol 2007, No 82 (2007) | How Virtual Biotech has Changed the World | Abstract html |
| Fintan Walton | ||
| Vol 2008, No 92 (2008) | Human Genome Sciences Boosts Cancer Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 4 (2011) | Human Genome Sciences Licenses FivePrime Therapeutics’ Lead Cancer Drug | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 10 (2013) | Hutchison MediPharma Partners with Eli Lilly to Advance Development of Fruquintinib in China | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 87 (2007) | Icagen Agrees Licensing Deal with Pfizer | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | ICN to Market Pharmacia Products in Italy | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 28 (2002) | IDEC and Caprion Pharmaceuticals to Search for Novel Cancer Antigen Targets | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | IDEC Pharmaceuticals and Biogen | Abstract |
| Business Review Editor | ||
| Vol 2018, No 2 (2018) | Idera and BioCryst Merge to Form Rare Disease Company | Abstract html pdf |
| Natasha Piper | ||
| Vol 2005, No 59 (2005) | IDM’s and Epimmune’s Merger Highlights Biotech Funding Difficulties | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | Igeneon Licenses Cancer Vaccine from Novartis | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 6 (2022) | Immatics and Bristol Myers Squibb Expand Alliance to Develop Cell Therapy Programmes | Abstract pdf html |
| Swati Sharan | ||
| Vol 2025, No 1 (2025) | Immedica Pays US$151 M to Acquire Marinus Pharmaceuticals | Abstract pdf html |
| Naini Anand & Lucy Haggerty | ||
| Vol 2002, No 27 (2002) | Immune Network Signs Two Deals for hNM01 Antibody | Abstract |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | Immunex sells cancer drug to Schering AG for US$380 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 7 (2013) | Immunocore’s ImmTAC ® Platform Gains Big Pharma Recognition with Genentech Pact | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 9 (2023) | Immunogen Collaborates with Takeda to Develop and Commercialise Elahere® in Japan | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2023, No 3 (2023) | ImmunoGen Signs Partnership with Vertex for Conditioning Agents worth US$352 M | Abstract pdf html |
| Swati Sharan | ||
| Vol 2017, No 3 (2017) | Immunomedics and Seattle Genetics enter into US$2 B Deal for Sacituzumab Govitecan | Abstract pdf html |
| Natasha Piper | ||
| Vol 2006, No 72 (2006) | Immunomedics Relights its Therapeutic Potential | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 2 (2012) | Impax In-Licenses US Commercial Rights to AstraZeneca’s Migraine Drug Zomig® | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 9 (2016) | IMS PharmaDeals Half Year Review of 2016 | Abstract pdf |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2014, No 9 (2014) | IMS PHARMADEALS HALF-YEAR REVIEW 2014 | Abstract pdf |
| Taskin Ahmed & Heather Cartwright | ||
| Vol 2015, No 8 (2015) | IMS PharmaDeals Half-Year Review of 2015 | Abstract |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2015, No 3 (2015) | IMS PharmaDeals Review of 2014 | Abstract |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2016, No 3 (2016) | IMS PharmaDeals Review of 2015 | Abstract pdf |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2017, No 8 (2017) | IMS PharmaDeals: Half-Year Review of 2017 | Abstract pdf |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2017, No 3 (2017) | IMS PharmaDeals: Review of 2016 | Abstract pdf |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2005, No 64 (2005) | Increlex (mecasermin) | Abstract pdf |
| Business Review Editor | ||
| Vol 2025, No 2 (2025) | Incyte and Genesis Therapeutics Sign US$620 M AI-focused Collaboration | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2010, No 1 (2010) | Incyte Bags Another Big Pharma Collaboration | Abstract |
| Taskin Ahmed | ||
| Vol 2017, No 11 (2017) | Incyte Inks US$900 M Deal with MacroGenics to Develop PD-1 Inhibitor | Abstract pdf html |
| Jawala Prasad & Heather Cartwright | ||
| Vol 2020, No 1 (2020) | Incyte Pays US$900 M Upfront to Partner with MorphoSys for Tafasitamab | Abstract html pdf |
| Michelle Liu | ||
| Vol 2022, No 10 (2022) | Incyte to Acquire Villaris Therapeutics for US$1.43 B | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2011, No 12 (2101) | India’s Lupin Expands its Presence In Japan with I’rom Pharmaceutical Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 11 (2012) | India’s Sun Pharma Targets US Dermatology Market with Dusa Pharmaceuticals Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 66 (2005) | Indiplon | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | Infinity Licenses Intellikine’s Oral PI3K Therapies for Oncology and Inflammatory Diseases | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 56 (2005) | Infinity’s Small Molecule Collaborations with Big Pharma | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 73 (2006) | Inhalation Technologies - A Breath of Fresh Air | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 2 (2012) | Injections | Abstract jpg |
| Clive Goddard | ||
| Vol 2006, No 73 (2006) | Innate Pharma Advances Toll-like Receptor Research | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 68 (2006) | Innogenetics NV | Abstract |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | Innogenetics NV | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 75 (2006) | Innovata plc | Abstract |
| Business Review Editor | ||
| Vol 2007, No 79 (2007) | Insomnia | Details jpg |
| Business Review Editor | ||
| Vol 2009, No 5 (2009) | Integrating Data and Analyses of Pharmaceutical and Biotech Deals Information: The New Approach of PharmaDeals | Abstract |
| Anne Vindenes Allen | ||
| Vol 2022, No 2 (2022) | Intellia and ONK Collaborate on CRISPR-Edited Cancer Cell Therapies | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2007, No 85 (2007) | Intendis GmbH | Abstract |
| Business Review Editor | ||
| Vol 2010, No 5 (2010) | Intercell Acquires Monoclonal Antibody Assets from Cytos | Abstract |
| Debbie Tranter | ||
| Vol 2004, No 44 (2004) | Intercell AG | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 12 (2009) | Intercell and GSK in Alliance for Novel Patch Vaccines | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 5 (2012) | InterMune Divests Declining Actimmune® to Focus on Esbriet® | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 24 (2002) | IntraBiotics acquires Apothogen | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 8 (2012) | Intrexon and Synthetic Biologics Collaborate Again | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 89 (2007) | Inverness' Spree Continues | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 64 (2005) | Inyx Increases Capabilities in the Inhaled Drug Market | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 5 (2016) | Ionis Pharmaceuticals Selects Kastle Therapeutics as its New Commercial Partner for Kynamro® | Abstract pdf html |
| Natasha Berry, Jawala Prasad & Heather Cartwright | ||
| Vol 2020, No 1 (2020) | Ionis Signs Discovery Deals with Empirico and Aro | Abstract html pdf |
| Pratika Pahwa | ||
| Vol 2006, No 72 (2006) | IPOs: Still the Exit Strategy of Choice? | Abstract |
| Business Review Editor | ||
| Vol 2022, No 7 (2022) | Ipsen Acquires Epizyme to Broaden its Oncology Portfolio | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2012, No 8 (2012) | Ipsen and Inspiration Biopharmaceuticals Restructure Haemophilia Commercial Partnership | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 1 (2010) | Ipsen and Inspiration Collaborate on Haemophilia Developments | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 75 (2006) | Ipsen and Tercica Enter into Cross-Licensing and Equity Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 2 (2017) | Ipsen Boosts Oncology Pipeline with Merrimack’s Assets | Abstract pdf html |
| Jasmine Kalsi & Arun Manohar | ||
| Vol 2019, No 10 (2019) | Ipsen Boosts Rare Disease Portfolio with Blueprint’s BLU-782 | Abstract pdf html |
| Pratika Pahwa | ||
| Vol 2019, No 3 (2019) | Ipsen Boosts Rare Disease Portfolio with Clementia Acquisition | Abstract html pdf |
| Michelle Liu | ||
| Vol 2022, No 8 (2022) | Ipsen Enters Immuno-Oncology Partnership with Marengo Therapeutics for US$1.6 B | Abstract pdf html |
| Swati Sharan | ||
| Vol 2008, No 97 (2008) | Ipsen Expands Existing US Base through Acquisitions Worth $458 Million | Abstract pdf html |
| The PharmaDeals Team | ||
| Vol 2019, No 9 (2019) | IQVIA Pharma Deals Half-Year Review of 2019 | Abstract pdf |
| Heather Cartwright, Michelle Liu, Natasha Piper & Taskin Ahmed | ||
| Vol 2020, No 9 (2020) | IQVIA Pharma Deals Half-Year Review of 2020 | Abstract pdf |
| Heather Cartwright, Michelle Liu & Taskin Ahmed | ||
| Vol 2021, No 9 (2021) | IQVIA Pharma Deals Half-Year Review of 2021 | Abstract pdf |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2022, No 10 (2022) | IQVIA Pharma Deals Half-Year Review of 2022 | Abstract pdf |
| Heather Cartwright, Taskin Ahmed & Lucy Haggerty | ||
| Vol 2023, No 10 (2023) | IQVIA Pharma Deals Half-Year Review of 2023 | Abstract pdf |
| Lucy Haggerty,Swati Sharan & Taskin Ahmed | ||
| Vol 2024, No 9 (2024) | IQVIA Pharma Deals Half-Year Review of 2024 | Abstract pdf |
| Lucy Haggerty, Taskin Ahmed, Ayush Saxena & Swati Sharan | ||
| Vol 2020, No 3 (2020) | IQVIA Pharma Deals Review of 2019 | Abstract pdf |
| Heather Cartwright, Michelle Liu, Natasha Piper & Taskin Ahmed | ||
| Vol 2021, No 3 (2021) | IQVIA Pharma Deals Review of 2020 | Abstract pdf |
| Heather Cartwright, Michelle Liu & Taskin Ahmed | ||
| Vol 2022, No 3 (2022) | IQVIA Pharma Deals Review of 2021 | Abstract pdf |
| Heather Cartwright, Taskin Ahmed & Lucy Haggerty | ||
| Vol 2023, No 3 (2023) | IQVIA Pharma Deals Review of 2022 | Abstract pdf |
| Heather Cartwright, Taskin Ahmed & Lucy Haggerty | ||
| Vol 2024, No 3 (2024) | IQVIA Pharma Deals Review of 2023 | Abstract pdf |
| Lucy Haggerty, Ayush Saxena & Taskin Ahmed | ||
| Vol 2025, No 3 (2025) | IQVIA Pharma Deals Review of 2024 | Abstract pdf |
| Lucy Haggerty,Taskin Ahmed,Ayush Saxena & Shikha Kashyap | ||
| Vol 2018, No 9 (2018) | IQVIA Pharma Deals: Half-Year Review of 2018 | Abstract pdf |
| Heather Cartwright, Natasha Piper & Taskin Ahmed | ||
| Vol 2019, No 4 (2019) | IQVIA Pharma Deals: Review of 2018 | Abstract pdf |
| Michelle Liu, Natasha Piper, Heather Cartwright & Taskin Ahmed | ||
| Vol 2021, No 11 (2021) | Ironwood Begins to Rebolster its Pipeline with Cour’s Rare Disease Drug | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 9 (2018) | Ironwood Ends US$265 M Gout Collaboration with AstraZeneca | Abstract pdf html |
| Michelle Liu & Heather Cartwright | ||
| Vol 2012, No 11 (2012) | Ironwood Pharmaceuticals Chooses AstraZeneca as Chinese Partner for Linaclotide | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 2 (2012) | Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 5 (2023) | Ironwood to Acquire Rare Disease Specialist VectivBio for US$1 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 3 (2009) | Is Allergan the Next Takeover Target? | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 4 (2009) | Is This the Calm After the Storm? | Abstract |
| Taskin Ahmed | ||
| 1301 - 1400 of 2581 Items | << < 9 10 11 12 13 14 15 16 17 18 > >> | |